TAIZHOU, China, Jan. 14, 2022 /PRNewswire/
-- China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) ("China
SXT" or the "Company"), a specialty pharmaceutical company focusing
on the research, development, manufacturing, marketing, and sales
of Traditional Chinese Medicine Pieces ("TCMPs"), including
Advanced TCMPs (Directly-Oral TCMP and After-Soaking-Oral TCMP),
fine TCMPs, regular TCMPs, and TCM Homologous Supplements
("TCMHS") announced today that it develops and
commercializes the Kuihuapan After-Soaking-Oral TCMP and Zhudanfen
Directly-Oral TCMP products. The Kuihuapan products are produced
according to the four processing specifications of Chinese
Pharmacopoeia (2020 Edition) No. 34 of China Heilongjiang food and
Drug Administration Note Letter [2020], and have the functions of
clearing heat, calming liver, dredging collaterals and relieving
pain. Its indications include dizziness, tinnitus, joint pain,
hyperuricemia, gout, hypertension and other symptoms. The Zhudanfen
products are produced according to the processing specifications of
Chinese Pharmacopoeia (2020 Edition), it has the functions of
clearing heat and moistening dryness, relieving cough and asthma,
and detoxifying, and is suitable for sudden cough, asthma, fever,
thirst, red eyes, throat obstruction, jaundice, diarrhea,
dysentery, constipation, sores, carbuncle, swelling and poison.
Zhudanfen is also listed in the National Medical Insurance
Catalogue (No. 697 of the National Medical Insurance Catalogue). We
expect that the annual output of both Kuihuapan and Zhudanfen to
reach 300,000 bottles, and achieve the sales of about RMB 5 million during the fiscal year ending
March 31, 2023.
In addition, although the GMP compliance inspection conducted by
Jiangsu Province Medical Products Administration (JSMPA) for
the Company's new lyophilization production facilities in
June 18, 2021 delayed the production
cycle and the production capacity decreased consequently, compared
with the same period. JSMPA completed its inspection in
June 20, 2021. As of December 31, 2021, there are 12 batches of
Luxuejin Directly-Oral TCMP products produced by
lyophilization process. The Company has consumed 2.08 tons of
fresh bloods of Cuerus Nippon as the raw materials, and
the total amount of Luxuejin after freeze-drying is 316.92
kilogram, which is expected to achieve the sales of more than
RMB 3 million during the fiscal year
ending March 31, 2022. With the
continuous increased market demand for Luxuejin, we will work to
increase our production capacity and we believe the output value
will grow rapidly.
According to the definition of Directly-Oral TCMP and the
preclinical research and development strategies of new medicine of
FDA and CFDA, our R&D Department chose the standards under the
"processing" and "usage" parts of the corresponding TCMPs in the
Chinese Pharmacopoeia (2015 Edition), and applies the latest
technology and analysis methods to systematically invent a new type
of Directly-Oral TCMP product which can be directly taken orally or
infused without decoction, and maintains all the original effective
components. Thus, it improves clinical curative effects, saves
medicinal materials, is easy to carry, and can be stored easily.
After-Soaking-Oral TCMP products are another new type of Advanced
TCMP that can be brewed in boiling water (similar to tea drinking
method), which first appeared in part 4 of Chinese Pharmacopoeia
(2015 Edition). Its research and development method is similar to
that of Directly-Oral TCMP, and our R&D Department
systematically developed a new product series of After-Soaking-Oral
TCMP according to the characteristics of its which can be directly
brewed with boiling water (or decocted with the traditional TCMP
formula), so as to maintain the original effective ingredients to
the greatest extent and improve the clinical effects.
"The developed R&D and production of Advanced TCMP products
will greatly help us make continuous efforts in leading the R&D
of Advanced TCMP and pursuing higher quality products. We believe
that this will further expand the market shares of our
Directly-Oral TCMP and After-Soaking-Oral TCMP products ", Mr.
Feng Zhou, Chief Executive Officer
of China SXT, commented.
About China SXT Pharmaceuticals, Inc.
Founded in 2005 and headquartered in Taizhou City, Jiangsu
Province, China, China SXT Pharmaceuticals, Inc. is an
innovative pharmaceutical company focusing on the research,
development, manufacture, marketing and sales of traditional
Chinese medicine pieces, which is a type of Traditional Chinese
Medicine that has been processed to be ready for use. For more
information, please visit www.sxtchina.com
Safe Harbor Statement
This press release contains forward-looking statements as
defined by the Private Securities Litigation Reform Act of 1995.
Forward-looking statements include statements concerning plans,
objectives, goals, strategies, future events or performance, and
underlying assumptions and other statements that are other than
statements of historical facts. When the Company uses words such as
"may, "will, "intend," "should," "believe," "expect," "anticipate,"
"project," "estimate" or similar expressions that do not relate
solely to historical matters, it is making forward-looking
statements. Specifically, the Company's statements regarding the
closing of the proposed private placement are forward-looking
statements. Forward-looking statements are not guarantees of future
performance and involve risks and uncertainties that may cause the
actual results to differ materially from the Company's expectations
discussed in the forward-looking statements. These statements are
subject to uncertainties and risks including, but not limited to,
the following: the Company's goals and strategies; the Company's
future business development; product and service demand and
acceptance; changes in technology; the growth of the pharmaceutical
market, particularly the Traditional Chinese Medicine Pieces
("TCMPs") market, in China; reputation and brand; the impact
of competition and pricing; government regulations; fluctuations in
general economic and business conditions in China and the
international markets the Company serves and assumptions underlying
or related to any of the foregoing and other risks contained in
reports filed by the Company with the Securities and Exchange
Commission. For these reasons, among others, investors are
cautioned not to place undue reliance upon any forward-looking
statements in this press release. Additional factors are discussed
in the Company's filings with the U.S. Securities and Exchange
Commission, which are available for
review at www.sec.gov. The Company undertakes no
obligation to publicly revise these forward - looking
statements to reflect events or circumstances that arise after the
date hereof.
View original
content:https://www.prnewswire.com/news-releases/china-sxt-pharmaceuticals-inc-adds-newly-developed-kuihuapan-and-zhudanfen-advanced-tcmp-products-and-announces-the-expected-continuous-growth-of-its-production-capacity-of-luxuejin-301461342.html
SOURCE China SXT Pharmaceuticals, Inc.